In fact, S2R has been proposed as a therapeutic target for the treatment of a variety of neurodegenerative diseases, including not only Alzheimer’s disease but also Parkinson’s disease and retinal diseases, such as the dry form of age-related macular degeneration [11,21]. The gene discussed is TMEM97; the disease is early-onset autosomal dominant Alzheimer disease.